Substituting lower-wage staff for registered nurses tied to worse outcomes
Jun 25, 2024
Harms include avoidable patient deaths, readmissions, longer lengths of stay, excess Medicare costs and forgone cost savings.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.